Download CURRICULUM VITAE

CURRICULUM VITAE
Darrel Edmund Drachenberg BSc, MD, FRCS(C)
Assistant Professor of Surgery, Director of Research,
Manitoba Prostate Centre and Section of Urology, Faculty of Medicine, University of Manitoba,
Chair, Genitourinary Disease Site Group, Cancer Care Manitoba
Academic office:
Clinical office:
Fax:
Email:
(204) 237-2571
(204) 235-3713
(204) 237-3429
ddrachenberg@sbgh.mb.ca
Teaching file/ Academic/Clinical:
Assistant Professor, Department of Surgery, Section of Urology –University of Manitoba
Academic Duties-Resident Teaching and Research, Medical School preceptorship and Curriculum Planning
& Lectures
Perform majority of Oncology surgeries and all laparoscopic and minimally invasive procedures
(brachytherapy, cryotherapy, HIFU, RFA) for the province of Manitoba population over 1 million people
Adept at all urologic laparoscopic procedures including laparoscopic Radical Nephrectomy, laparoscopic
partial nephrectomy, laparoscopic adrenalectomy, laparoscopic radical prostatectomy, laparoscopic
pyeloplasty
Experience with Urologic uses of ROBOTICS including AEOSOP and DA VINCI
Started the Manitoba Prostate Brachytherapy program, Cryotherapy program, and HIFU programs and RFA
programs and continue to lead these minimally invasive approaches to treatment of prostate and renal
cancers
Director of Research Department of Surgery, Section of Urology –University of Manitoba
Director of Research Manitoba Prostate Center
Chair- GU Oncology Disease Site Group- Cancer Care Manitoba –clinical trials management, basic science
coordination, weekly multidisciplinary rounds organization, treatment guidelines for province of Manitoba
GU cancers, etc
Chair Manitoba Medical Association –Urology Section
Quality Assurance Reviewer College of Physicians and Surgeons Manitoba Chapter
Residency
Chief Resident Dalhousie University- 1999-2000, in charge of resident education, departmental academic
program, operative instruction to residents, tertiary care consult service, proficient in all operative urologic
procedures
Examiner- 4th year medical school OSCE/Oral Examinations-1999-2000
Medical Student teaching in Urology- 1995-2000
Reviewer:








Reviewer – Canadian Urological Association Annual Meeting Scientific Committee (2011)
Reviewer -Urology (2010)
Reviewer – Journal of Canadian Urologival Association (2010)
Reveiwer – Canadian Journal of Urology (2010)
Reviewer – Lancet Oncology (2010)
Journal of Urology
Cancer Treatement Reviews
Editorial board member and reviewer of educational information of MDCONVERSATION- a company
dedicated to dissemination of medical information to patients through the internet and computer based learning
2
Memberships:
Royal College of Physicians and Surgeons of Canada- Active Member
American Urological Association- Active Member
Canadian Urological Association- Active Member
Canadian Urological Association Exectuive Committee – Chair of the Socioeconomic committee
Canadian Urologic Oncology Group – Executive Committee member – Prairie Regional Head
Chair Genito-Urinary Oncology – Disease Site Group, Cancer Care Manitoba
Doctors Manitoba – Urology lead
Society of Urologic Oncology- Active Candidate Member
National Cancer Institute Canada – Exectuive Committee member
Endourological Society- Active Member
Manitoba Medical Association- Active Member
Canadian Medical Association- Active Member
CUA Scientific Committee (executive member)
Nova Scotia/ New Brunswick Medical Society- Past Member
British Columbia Medical Association- Past Member
Kidney Cancer Canada, Medical Advisory Board member & Executive Committee Member
Canadian Bladder Cancer Network – Executive Committee Member
CME Prostate Health.COM – Exectuive Committee Member
Education
Fellowship training: Urologic Oncology/Laparoscopic Urology
National Cancer Institute/National Institute of Health, Washington, DC
July 2000-June 2002- became adept at minimally invasive oncologic surgery with laparoscopy and percutaneous and
laparoscopic radiofrequency ablation; experience with Urologic use of ROBOTICS including AEOSOP and DA
VINCI. Became exposed to and mounted research projects in the molecular immunology of GU malignancies.
Awards and Honors
2000
Society of Urologic Oncology First Prize- Genetic Immunization with Prostate Specific Genes
leading to Anti-prostate Autoimmunity as a novel model for Prostate Cancer Vaccination
2000 -2002 American Foundation of Urologic Diseases (AFUD)/National Cancer
Institute Research Scholar
Post Graduate Training: Urology Residency
Dalhousie University, Halifax, Nova Scotia
June 1995-June 2000
Awards and Honors
1999
1999
1999
1998
Department of Urology Research Day First Prize-Autoimmune Prostatitis after Genetic
Immunization with Probasin and Probasin/IL-12 by Gene Gun Technology and IM
Injections
Urology Times of Canada Writing Award Winner First Prize- “The Final Inning”
Dissertation about dealing with Terminal Prostate Cancer
Department of Urology Research Day First Prize- Telomerase Activity in Bladder
Cancer and Exfoliated Cells in Urine
Faculty of Medicine Research Day First Prize- Telomerase Activity in Bladder Cancer
and Exfoliated Cells in Urine
Medical School:
University of British Columbia, Vancouver, British Columbia
August 1990-May 1995
Awards and Honors
3
1995
Rakesh-Goel Graduation Prize- for overall excellence in all clinical
disciplines of medicine throughout medical school
1994
Outstanding Physician/Scientist Award - Society of Nuclear Medicine
19th annual western regional meeting The Use of PSA and Bone Scan in
Patients With Prostate Cancer at Time of Diagnosis
1993
B.C. Medical Services Foundation Bursary - for demonstration of
academic excellence in the faculty of medicine
1993
Harold James Russell Memorial Bursary - for overall character and
academic achievement
1993
Schom Memorial Bursary
1992
Samuel Diamond Scholarship - for academic excellence in Medicine
1991/92 Microtel Pacific Research Academic Achievement Scholarship
1991
Medical Research Council of Canada Undergraduate Research Award
Undergraduate University Studies:
Simon Fraser University, Burnaby, British Columbia
B.Sc., Molecular Biology / Certificate in Liberal Arts
Co-operative Education Degree
September 1984 - April 1990
Awards and Honors
1990&1991
1989&1990
1985-1990
1985-1990
1984-1986
1984-1985
Medical Research Council of Canada Undergraduate Research Award
Natural Science and Engineering Research Council Award 1988
Presidents Scholarship Microtel Pacific Research Centre - for outstanding academic
achievement, citizenship, overall character and athletic ability
Microtel Pacific Research Academic Achievement Award
Deans Honor Roll of Simon Fraser University - for placing in top two
percent of university students
Provincial Academic Achievement Award
Chancellor's Scholarship, - S.F.U. for highschool academic excellence
Research Experience
Current Research Positions:
Assistant Professor of Surgery, Director of Research
Manitoba Prostate Centre and Section of Urology, Faculty of Medicine,
University of Manitoba
Chair, Genitourinary Oncology Disease Site Group
Cancer Care Manitoba
(Clinical Trial Activity 2010 as Principal Investigator)
PR11-A Phase III Study of Active Surveillance Therapy Against Radical
Treatmentin Patients Diagnosed with Favourable Risk Prostate Cancer
(START)
PRC.3— A Randomized Phase III Study of Neo-Adjuvant Docetaxel and
Androgen Deprivation Prior to Radical Prostatecomy Versus Immediate
Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate
Cancer
REC.2— ASSURE: A Randomized Phase III Study of Adjuvant Sorafenib or
Sunitinib for Unfavourable Renal Carcinoma
Tax 3503- A Randomized, Open-Label, Multi-Centre, Phase III, 2-Arm Study of
Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically
Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive
Local Therapy .
4
PREVAIL- A Randomized Phase III Study of MDV 3100 vs Placebo in Chemo
Naïve Metastatic Hormone Refractory Prostate Cancer
SALVAGE HIFU- A Phase III, Multi-Centre Investigation of the Sonablate 500PC System Using High Intensity Focused Ultrasound (HIFU) for the Treatment
of Locally Recurrent Prostate Cancer after Failed Radiotherapy
July 2002 – 2010
ATLAS: prostate cancer trial of immediate vs delayed chemo-hormonal
therapy with LHRH agonist and taxotere for high risk prostate cancer treatment
CHICS:
cancer
dose escalation bicalutamide for androgen independent prostate
CORAL: the use of oral bisphosphonates ffoxamax to prevent bone loss in
patients on androgen ablation therapy
Pseudomonas endotoxin Vincinium for the treatment of superficial BCG
refractory bladder cancer
BL8: randomized phase III trial comparing immediate verses deferred
chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+Mo
transitional cell carcinoma of the bladder
BL. 11: a phase III study of Iressa® in Association with Intravesical BCG
versus Intravesical BCG alone in high risk superficial transitional cell
carcinoma of the bladder
PR7: a prospective phase 3 study randomising patients with rising PSAs after
radiation therapy to either continuous or intermittent androgen suppression
PR8: a prospective phase 3 study randomising patients with newly diagnosed
D2 prostate cancer toeither continuous vs intermittant androgen suppression
Comparison of prostate volumes pre and post brachytherapy implantation with
MRI, CT and TRUS ultrasound
The effect of treatment volume on brachytherapy treatment planning post seed
implantation in prostate brachytherapy
Circulating levels of spontaneous autoantibodies to NGF in patients with
prostate cancer
In VITRO activity of anti NGF IgM to promote apoptosis and inhibit migration
and cell growth and division of LN CAP prostate cancer cell line
Prostate cancer biomarkers discovery using high throughput proteomics
The expression of sonic hedgehog protein and cxcr 4 in BPH, PIN, localized
and locally advanced and metastatic prostate cancer
The expression of Von Hippel Lindau gene in renal cell cancer of patients with
Native Canadian heritage
The use of laparoscopic ligasure sealing system in urologic laparoscopy
The use of radio frequency ablation in patients with small renal masses
Cryotherapy for localized prostate cancer
5
Cryotherapy as salvage treatment after radiation failure for treatment of
prostate cancer
MR diffusion imaging studies to differentiate benign from malignant renal
lesions
The role of endorectal coil MRSI for diagnosis of localized prostate cancer
HIFU for localized prostate cancer and as salvage after radiation failure
Clinical and oncologic outcomes of cystectomy in patients in the WRHA for the
treatment of muscle invasive bladder cancer-the last decade
July 2000-June 2002:
Immunotherapy of Renal Cell Carcinoma and Prostatic
Adenocarcinoma/mechanisms of antitumor immune response/ tumor vaccine
development through dendrtitic cell-tumor fusion/telomerase (hTert) expression
in dendrtic cell via infection with hTert retroviral expression vectors as a
mechanism to generate antitumor immunity in RCC and CaP/G250 expression
via retroviral vector infection of dendritic cells to generate antitumor immunity
in RCC/allogeneic chimerized T-lymphocte antitumor response in RCC after
allogeneic Bone Marrow Transplantation/ Antigen discovery in Renal cell
carcinoma/prostate adenocarcinoma / Genotypic and Phenotypic differences in
RCC characterized via differences in DNA microarray expression analysis in
G250 positive and negative RCC and Von-hippel-lindau mutation positive and
negative RCC/ Characterization of expression of G250 tumor antigen in RCC
and VHL mutation analysis and the pathway of tumorigenesis of mutant
VHLprotein and trans-membrane G250
Supervisors: Dr. WM. Linehan/Dr. R Childs
June 1995-June 2000:
Dept. of Urology, Dalhousie University
Telomerase Activity in Urologic Malignancies/ Prostate Cancer Vaccine
Development using PSMA Genetic Therapy/ A Model of Autoimmune Prostatitis
Using Probasin/Il-12 Constructs, Genetic Immunization, and Gene Gun
Technology
Supervisor: Dr. David Bell/Dr. Ken West
Radical Prostatectomy and Sexual Dysfunction
Supervisor: Dr. John Grantmyre
Patient Satisfaction after Hypospadius Repair
Supervisor: Dr. Peter Wentzell
May 1993-Aug.1993:
Researcher,
Dept. of Urology/Dept. of Nuclear Medicine, UBC
Ability of Serum PSA to Predict Normal Bone Scans in
Untreated Prostate Cancer (see publications below)
Supervisors: Dr. M.E. Gleave, M.D. & Dr. D. Coupland, M.D.
May 1991-Aug. 1991: Research Assistant, Dept. of Pathology, Vancouver
General Hospital, Identification, Cloning, and Characterization of the Gene for
Porphobilinogen Deaminase -to screen for patients with Acute Intermittent
Porphyria.
Supervisor: Dr. Wes Schreiber, M.D.
May 1990-Aug. 1990:
Research Assistant,
Dept. of Physiology, University to Manitoba
Identification and Characterization of Novel Immunosuppressive Proteins in
Prostatic Secretions
Supervisor: Dr. R. Matusik, PhD
6
Jan. 1989-Jan. 1990:
Co-operative Education Research Assistant
The Biomedical Research Centre, Vancouver, British Columbia Development of
an in vitro model of Paracrine Oncogenesis through the creation
of
retroviral expression vectors encoding interleukinSupervisor: Dr. K.
Leslie, M.D. , PhD.
Sept. 1988-Dec.1988:
Teacher Advisor/Laboratory Instructor;
Simon Fraser University, Burnaby, British Columbia
Biology Department
Instructor of upper level genetic analysis course BISC 302.
Supervisor: Dr. C. L. Kemp, PhD
Grants




Canadian Urologic Association Scolorship Fund 2003-2004
40000/yr renewable for 2 years
Sanofi-Aventis Investigator Grant- $90000 - cryotherapy for prostate cancer
Novartis Investigator Grant- $50000 - Basic Science prostate cancer research into antibodies to NGF in
localized and metastatic prostate cancer
Abbott Investigator Grant- $20000 towards prostate cancer research in basic sciences
Publications

Guideline for The Management of the Small Renal Mass(SRM). M. A.S. Jewett, R. Rendon, L. Lacombe, P. I.
Karakiewicz, S. Tanguay, W. Kassouf, M. Leveridge, I. Cagiannos, A. Kapoor, S. Pautler, D. Drachenberg, R.
Moore, M. Gleave, A. Evans, M. Haider. Canadian Urological Association - 2013

Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. Michael A.S.
Jewett, Kamal Mattar, Joan Basiuk, Christopher G. Morash, Stephen E. Pautler, D. Robert Siemens, Simon
Tanguay, Ricardo A. Rendon, Martin E. Gleave, Darrel E. Drachenberg, Raymond Chow, Hannah Chung,
Joseph L. Chin, Neil E. Fleshner, Andrew J. Evans, Brenda L. Gallie, Masoom A. Haiderm, John R. Kachuram,
Ghada Kurban, Kimberly Fernandes, Antonio Finelli. European Association of Urology, 2011.

Associations between age and clinical outcomes after radical cystectomy: results from the Canadian Bladder
Cancer Network Fairey A, Kassouf W, Aprikian A, Fradet Y, Lacombe L, Chin J, Izawa J, Cagiannos I, Lattouf
J, Rendon R, Bell D, Drachenberg D, Estey E in press Urologic Oncology - 2010

Outcomes of cT1G3 bladder cancer treated with radical cystectomy Canadian Bladder Cancer Network
experience; Izawa J, , Kassouf, W, Aprikian A, Fradet Y, Estey E, Fairey A,Rendon R, Cagiannos I, Lacombe
L, Lattouf J-B, Bell D, Drachenberg D, Chin J. In press Journal of Canadian Urological Association - 2010

The incidence of prostate cancer and urothelial cancer in the prostate in cystoprostatectomy specimens:
implications for oncologic surgery Sivalingam S, Drachenberg D- submitted Urology (Gold Journal) - 2010

Achieving pT0N0 at radical cystectomy: outcomes of 135 pT0N0 bladder cancer patients treated with radical
cystectomy: the Canadian Bladder Cancer Network experience Sandhu, G, Kassouf, W, Aprikian A, Chin J,
Fradet Y, Izawa J, Estey E, Fairey A,Rendon R, Cagiannos I, Lacombe L, Lattouf J-B, Bell D, Drachenberg Dsubmitted Journal of the Canadian Urological Association - 2010

Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer, M. Jewett, A.
Finelli, I. Link; C. Morash, J. L Chin, S. Pautler, R. Siemens; S. Tanguay, R. A. Rendon, M. E. Gleave, D.
Drachenberg, A. Evans, B. Gallie, M. Haider, J.Kachura, T. Panzarella, R. Chow, C. Ma, K. Mattar, N.
Fleshner – submitted Journal of Clinical Oncology - 2010

Impact of histology on outcomes of radical cystectomy: a series from the Canadian Bladder Cancer Network,
Cagiannos I, Morash C, Aprikian A, Fradet Y, Izawa J, Chin J, Estey E,Fairey A, Lacombe L, Lattouf J, Rendon
R, Bell D, Drachenberg D, Kassouf W submitted Journal of Urology - 2010
7

Clinical and pathological stage correlations in patients with bladder carcinoma: Canadian Bladder Cancer
Network experience Lattouf J-B, Kassouf W, Aprikian A, Fradet Y, Izawa J, Chin J, Estey E, Fairey A,
Caggianos I, Lacombe L, Rendon R, Bell D, Drachenberg D, Saad F submitted British Journal of Urology 2010

Impact of adjuvant chemotherapy on outcomes for patients with pT3-4 or pN+ bladder cancer treated with
radical cystectomy: Canadian Bladder Cancer Network experience Power E, Bell D, Kassouff W, Aprikian A,
Fradet Y, Lacombe L, Chin J Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf J-B, Drachenberg D, Rendon R
submitted Journal of Urology – 2010

Radical cystectomy for clinically muscle invasive bladder cancer: Does prior superficial disease affect clinical
outcomes? Ahmed F Kotb, Wassim Kassouf, Joe Chin, Yves Fradet Jonathan Izawa, Eric Estey Adrian Fairey,
Ricardo Rendon, Ilias Cagiannos, Louis Lacombe, Jean-Baptiste Lattouf, David Bell, Darrel Drachenberg,
and Armen G Aprikian submitted Journal of Urology - 2010

Primary testicular mucinous neoplasms: case report and literature review. J. Elliott, J. Klein, D.
Drachenberg. Can Urol Assoc J 2010; 4(4):E112-115.

Giant renal leiomyoma: a case report and brief review of the literature, M. Andreoiu, D. Drachenberg, and R.
MacMahon. Can Urol Assoc J. 2009 October; 3(5): E58–E60.

Physician opinion of the Privativzation of health care services in Canada: a survery of Canadian Urolgists by
the Canadian Urological Association Socioeconomic Committee, B. Mayson, N. Fleshner, D. Drachenberg.
Published CUAJ Volume 3, Nunber 3, June 2009
Management of Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. A. Abugaber, H.
Atwell, N Bajula, J Basiuk, P Black, N Blais, M Brigden, I Cagiannos, C Canil, F Carbonneau, T Chen, D
Drachenberg, N Drayton, K Durrant, A Evans, B Fairfield, R Grant, D Heng, J Kawakami, L Koltz, G Kurban,
K Kyryluk, I Link, I McAuley, J McCarthy, G Menard, J Michels, R Moore, C Morash, S North, N Pace, A
Pause, E Pituskin, T Pizioli, I Reid, D Ruether, A Shoker, K Sridhar, L Taylor, T Truong. Published June 2009
CUAJ.
The Role of 5-Alpha Reductase Inhibitors in Prostate Pathophysiology: Is There an Additional Advantage to
Inhibition of Type 1 Isoenzyme? L. Goldenberg, A. So, N. Fleshner, R. Rendon, D. Drachenberg, M. Elhilali.
Can Urol Assoc J. 2009 June; 3(3 Suppl 2): S109–S114.










Gleason Grading Controversies: What the Chemoprevention Trials Have Taught Us.
L. Klotz, D.
Drachenberg, Y. Fradet, F. Saad, J. Trachtenberg, A. Zlotta. Can Urol Assoc J. 2009 June; 3(3 Suppl 2):
S115–S120.
Prostate diseases: a primary care approach G Sandhu and DE Drachenberg Canadian Journal of CME
November/December 2009, Vol. 21, Number 11
Scrotal Masses- ensuring a correct diagnosis – M Andreou and DE Drachenberg Canadian Journal of CME
2007
Consensus Document: Recommendations for Optimal Surgical Wait Times for Patients with Urological
Malignancies Canadian Journal of Urology:Aprikian A, Bagnell S, Bell D, Donnelly B, Drachenberg D,
Dranitsaris G, Finelli A, Fleshner N, Fradet Y, Gleave M, Goldenberg L, Izawa J, Jewett M, Klotz L, Morash C,
Rendon R, Saad F, Short T,S iemens R, Tanquay S, Tsihlias J: June 2006: 13S: pp 62-64.
Does Prolonging the time to renal cancer surgery affect long-term cancer control? Asystematic review of the
literature- M Jewett, R Rendon, DE Drachenberg, G Dranitsaris, S Tanguay, B Donnelly, N Fleschner.
Candian Journal of Urology June 2006 13 (Supplement 3): 54-61
Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers, DE
Drachenberg, O.J. Mena, P.L. Choyke, W.M. Linehan, M.M. Walther- Journal of Urology- 2004
Jul;172(1):49-53.
Radical prostatectomy may improve disease-specific mortality, but not overall survival compared with watchful
waiting in early prostate cancer. DE Drachenberg, Cancer Treat Rev. 2003;29(3):231-3
Watchful waiting and radical prostatectomy have similar quality of life in localised prostate cancer. DE
Drachenberg; Cancer Treat Rev. 2003;29(3):235-7
8

Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement of
immune replacement. D. Drachenberg, R. Childs. The Urologic Clinics of North America. August 2003

Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. DE
Drachenberg and RW Childs; Cancer Treatment and research. 2003;116:213-26.

Ureteral fibroepithelial polyps: Current options for diagnosis and management- FS Leach, DE Drachenberg,
O Elbahloul, SE Pautler – Infect Urol 15(3):24-27, 2002

Simulataneous Preperitoneal Inguinal Herniorraphy during Radical Retropubic Prostatectomy- DE.
Drachenberg and DG Bell, Candian Journal of Urology, 9(4):1602-6, 2002
Nonmyeloablative stem cell transplantation in the treatment of Renal cell carcinoma, R Childs and DE
Drachenberg – Curr Opin Urol. 2001 Sep;11(5):495-502



Retroperitoneoscopic-guided radiofrequency ablation of renal tumors Pautler SE, Pavlovich CP, Mikityansky
I, Drachenberg DE, Choyke PL, Linehan WM, Wood BJ, Walther MM. Can J Urol 2001 Aug;8(4):1330-3
The Treatment of Early Stage Prostate Cancer DE. Drachenberg- Seminars in Surgical Oncology 18(1); 3744, 2000

Circulating Levels of IL-6 in Patients with Hormone Refractory Prostate Cancer- DE. Drachenberg, AA
Elgamel, R Rowbotham, M Peterson, GM Murphy. Prostate 41:127-133,1999

Genetic Immunization and Treatment of Prostate Cancer- DE. Drachenberg and GM Murphy,
Chronicle of Urology and Sexual Medicine August 1999 Vol. 5 No. 4

Urologic Manifestations of Minimal Trauma in the Elderly - DE. Drachenberg, MA Fischer, RW NormanThe Chronicle of Urology and Sexual Medicine- September 1999 Vol. 5 No. 5

Penile Entrapment Injury- Diagnosis, Management, and Case Review DE. Drachenberg, C. Nguan, RW.
NormanJ. Lawen Canadian Journal of Urology 6(1); 709-12, 1999.

Renal Cell Carcinoma in a Pelvic Kidney- M Fischer, A Carlsson, DE. Drachenberg, Gupta, Norman- BJU Int
1999 Mar;83(4):514

Early Detection of Bladder Cancer DE. Drachenberg- The Chronicle of Urology and Sexual Medicine
October 1998 Vol. 4 No. 5.
The

Prostate Cancer: Benefits of Screening and Early Detection DE. Drachenberg - The Chronicle of Urology
and Sexual Medicine October 1998 Vol. 4 No. 5.

Screening for Genitourinary Malignancies DE. Drachenberg- The Chronicle of Urology
Medicine September 1998 Vol. 4 No. 4.

Is ICSI the Solution to Male Infertility- DE. Drachenberg, J. Grantmyre- The Canadian
Journal Diagnosis October 1997, 75-85
and Sexual
 Erectile Dysfunction: A Guide to Treatment -DE. Drachenberg, J. Grantmyre -The Canadian Journal of
Continuing Medical Education 9: 2; 169-185, 1997.

Ability of Serum PSA levels to Predict Normal Bone Scans in Patients with Newly Diagnosed Prostate
Cancer -M.E. Gleave, DE. Drachenberg, D.B. Coupland, L.D. Sullivan, S.L. Goldenberg - Urology 47: 708712, 1996.

Telomerase Activity as a Novel Marker for TCC Bladder in Voided Urine Specimens- DE. Drachenberg,
Urosearch December 1996, Dalhousie University
9
Manuscripts in Preparation

Utility of a novel in vivo prostate magnetic resonance spectroscopic imaging technique Venugopal N, Sandhu
G, Al Mehairi S, Alamri A, Saranchuk J,McCurdy B, , Drachenberg D, Ryner L

Clinico-pathological correlation between radical prostatectomy specimens and in vivo prostate magnetic
resonance spectroscopic imaging Venugopal N, Sandhu G, Al Mehairi S, Alamri A, Saranchuk J,McCurdy B,
Ryner L, Drachenberg D

The Natural History of Small Renal Masses a systematic review of 250 patients- D Pruthi and DE Drachenberg

Bosniak classification of cystic renal masses – a real world analysis – D Pruthi and DE Drachenberg

Heterogeneity of High Risk Prostate Cancer- Does PSA level Matter apart from Gleason score? M Cenokowski
and DE Drachenberg

Isolated Caval Recurrence in Renal Cell Cancer - D Pruthi and DE Drachenberg

Spontaneous Regression of Biopsy Proven Renal Cell Carcinoma of the Kidney G Jawanda and DE
Drachenberg

Predictive value of Diffusion weighted MRI for cystic renal cell carcinoma in suspicious cystic renal masses- S
Rehsia, I Kirkpatrick, DE Drachenberg
Manuscripts Accepted for Publication

Examining Age and Survival Outcomes After Radical Cystectomy, Drachenberg, D, . Urologic Oncology:
Seminars and Original Investigations - 2011
Textbook Chapters:

The patient presenting with hematuria, DE Drachenberg and K Mattar; in Supportive Care for the Urology
Patient. 2006

Screening for Prostate Cancer in Patients with Benign Prostatic Hyperplasia- Chapter – in Textbook of Benign
Prostatic Hyperplasia- DE. Drachenberg and MK Brawer; eds R Kirby et al.; second edition 2006

Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to
immune replacement. DE Drachenberg and RW Childs;
Urol Clin North Am. 2003;30(3):611-22.

Low intensity allogeneic stem cell transplantation for metastatic renal cell cancer- Chapter- in Kidney CancerDE Drachenberg and RW Childs; ed RA Figlin; first edition 2003

Screening for Prostate Cancer Chapter 38B –in Comprehensive Textbook of Genitourinary Oncology- DE.
Drachenberg and MK Brawer; eds. NJ Vogelazang, PT Scardino, WU Shipley, DS Coffey; second edition
2000 .
10
Abstracts Published:

CUA-CUOG guidelines for the management of castration resistant prostate cancer (CRPC): 2013 update.
F. Saad, S. Hotte, C. Catton, D. Drachenberg, A. Finelli, N. Fleshner, M. Gleave, A. Kapoor, W. Kassouf, A.
Loblaw, S. North, N. Usmani, K.N. Chi. CUAJ August 2013, Volume 7, Issues 7-8.

The incidence of prostate cancer and urothelial cancer in the prostate in cystoprostatectomy specimens in a
tertiary care Canadian centre. S. Sivalingam, D. Drachenberg. Can Urol Assoc J. 2013 Jan-Feb;7(1-2):35-8.

Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in
Canada. M.l Metcalfe, W. Kassouf, R. Rendon, D. Bell, J. Izawa, J. Chin, A. Kapoor, E. Matsumoto, J.B.
Lattouf, F. Saad, L. Lacombe, Y. Fradet, A. Fairey, N. E. Jacobson, D. Drachenberg, I. Cagiannos, A. So, P.
Black. Candian Urological Association Journal, December 2012, Volume 6, Issue 6.

Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant
chemotherapy in a contemporary North-American multi-institutional cohort. N. E. Power, W. Kassouf, D. Bell,
A. G. Aprikian, Y. Fradet, L. Lacombe, J. Chin, J. Izawa, E. Estey, A. Fairey, I. Cagiannos, J. B. Lattouf, D.
Drachenberg, R. A. Rendon. Candian Urological Association Journal. December 2012, Volume 6, Issue 6.

Spontaneous regression of biopsy proven primary renal cell carcinoma: A case study. G.G. Jawanda, D.
Drachenberg. Canadian Urological Asociation Journal. October 2012, Volume 6, Issue 5.

A Pilot Study on the Effects of Home-Based Walking Exercise on Fracture Risk Factors in Men with Prostate
Cancer Receiving Androgen Deprivation Therapy. C. Lee, P. Czaykowski, J. Gingerich, J. Sathya, D.
Drachenberg, D. Kriellaars, L. Weinberg, W. Leslie, Y.K. Lau. Austrialian-Canadian Prostate Cancer
Research Alliance Symposium, August 2010

Brachytherapy as Monotherapy for Clinically Localized Intermediate-Risk Prostate Cancer: Biochemical
Outcomes and Toxixity Profile. S. Sivalingam, D. Drachenberg, A. Chowdhury. Canadian Urological
Association, June 2010.

Stage-Based Approach to Surveillance Following Radical Cystectomy in Bladder Cancer Patients. F. Yafi, A.
Aprikian, Y. Fradet, J. Chin, J. Izawa, R. Rendon, E. Estey, A. Fairey, I, Cagiannos, L. Lacombe, J. Lattouf, D.
Bell, D. Drachenberg, W. Kassouf. Canadian Urological Association, June 2010.

Radical Cystectomy for Clinically Muscle Invasive Bladder Cancer: Does Prior Superficial Disease Affect
Clinical Outcomes? A. Kotb, W. Kassouf, J. Chin, Y. Fradet, J. Izawa, E. Estey, A. Fairey, R. Rendon, I.
Cagiannos, L. Lacombe, J. Lattouf, D. Bell, D. Drachenberg, A. Aprikian. Canadian Urological Association,
June 2010.

Clinical Experience using in vivo Prostate Spectroscopic Imaging Technique at Short Echo Times. G. Sandhu,
N. Venugopal, B. Lategan, S. Sivalingam, S. Al-Mehairi, A. Al-Amri, B. McCurdy, L. Ryner, I. Al-Jada, D.
Drachenberg, Canadian Urological Association, June 2010.

Outcome of 304 Clinical T1G3 Bladder Cancer Patients Treated with Radical Cystectomy: The Canadian
Bladder Cancer Network Experience. Izawa J, Chin J, Chalasani V, Aprikian A, Fradet Y, Estey E, Fairey A,
Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W. CUAJ • June 2009 •
Volume 3, Issue 3(3Suppl1).

Impact of Histology on Outcomes of Radical Cystectomy: A Series from the Canadian Bladder Cancer Network.
Cagiannos I, Morash C, Aprikian A, Fradet Y, Izawa J, Chin J, Estey E, Fairey A, Lacombe L, Lattouf J,
Rendon R, Bell D, Drachenberg D, Kassouf W. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).

Active Surveillance of Small Renal Masses: A Prospective Multicenter Canadian Trial. Jewett M, Link I,
Morash C, Chin J, Pautler S, Siemens R, Tanguay S, Rendon R, Gleave M, Drachenberg D, Evans A, Chow R,
Mattar K, Finelli T. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1)

Outcome of 2287 Bladder Cancer Patients Treated with Radical Cystectomy: The Canadian Bladder Cancer
Network experience. Yafi F, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I,
Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).
11

Achieving pT0N0 at Radical Cystectomy: Outcomes of 135 Pt0n0 Bladder Cancer Patients Treated with
Radical Cystectomy: The Canadian Bladder Cancer Network Experience. Drachenberg D, Aprikian A, Chin
J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf J-B, Bell D, Kassouf W.
CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).

Associations Between Age and Clinical Outcomes After Radical Cystectomy: Results from the Canadian
Bladder Cancer Network. Fairey A, Kassouf W, Aprikian A, Fradet Y, Lacombe L, Chin J, Izawa J, Cagiannos
I, Lattouf J, Rendon R, Bell D, Drachenberg D, Estey E. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).

Clinical and Pathological Stage Correlations in Patients with Bladder Carcinoma: Canadian Bladder Cancer
Network Experience. Lattouf J-B, Kassouf W, Aprikian A, Fradet Y, Izawa J, Chin J, Estey E, Fairey A,
Caggianos I, Lacombe L, Rendon R, Bell D, Drachenberg D, Saad F. CUAJ • June 2009 • Volume 3, Issue
3(3Suppl1).

Impact of Adjuvant Chemotherapy on Outcomes for Patients with pT3-4 or pN+ Bladder Cancer Treated with
Radical Cystectomy: Canadian Bladder Cancer Network. Power E, Bell D, Kassouff W, Aprikian A, Fradet Y,
Lacombe L, Chin J, Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf J-B, Drachenberg D, Rendon R. CUAJ •
June 2009 • Volume 3, Issue 3(3Suppl1).

The Incidence of Prostate Cancer and Urothelial Cancer in the Prostate in Cystoprostatectomy Specimens.
Sivalingam S, Drachenberg D. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).

Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: The Manitoba Experience.
Czaykowski P, Drachenberg D. CUAJ • June 2009 • Volume 3, Issue 3(3Suppl1).

Utility of a novel in vivo prostate magnetic resonance spectroscopic imaging technique. Venugopal N, Sandhu
G, Al Mehairi S, Alamri A, Saranchuk J, McCurdy B, Ryner L, Drachenberg D. CUAJ • June 2009 • Volume 3, Issue
Alamri A,
3(3Suppl1).

Active Surveillance of Small Renal Masses: A Prospective Multi-Center Canadian Uro-Oncology Group Trial:
M. Jewett*, A. Finelli, I. Link; C. Morash, J. L Chin, S. Pautler, R. Siemens; S. Tanguay, R. A. Rendon, M. E.
Gleave, D. Drachenberg, A. Evans, B. Gallie, M. Haider, J.Kachura, T. Panzarella, R. Chow, C. Ma, K.
Mattar, N. Fleshner. American Urological Association J. May 2009

Contemporary outcomes of radical cystectomy in 2287 patients with transitional cell carcinoma of the bladder:
A Canadian multi-institutional experience, F. A. Yafi*, A. G. Aprikian, Y. Fradet, J. I. Izawa, J. L. Chin, E. P.
Estey, M. P. Chetner, I. Cagiannos, L. Lacombe, J. Baptiste Lattouf, R. A. Rendon, D. Bell, D. Drachenberg,
W. Assouf. American Urological Association J., May 2009

Active Surveillance of Small Renal Masses: A Prospective Multi-Centre Canadian Trial, K. Matar, J. Basiuk,
A. Finelli, N. Fleshner, S. Pautler, J. Chin, C. Morash, R. Siemens, R. Rendon, M. Gleave, S. Tanguay, D.
Drachenberg, A. Evans, B. Gallie, M. Haider, J. Kachura, T. Panzarella, M. Jewett, EUA 2008 Best Poster
Presentation

Postimplant Dosimetric Assessment of Transperineal Interstital Permanent Prostate Brachytherapy:
Improvement in Quality of Implant Over Time in a Single Institution, K. Malkoske, A. Chowdhury, D.
Drachenberg, accepted for publication September, 2008

Pulmonary Seed Embolization after Transperineal Interstitial Prostate Brachytherapy: Does Small Prostate
Gland or Seed Placement Outside Prostate Capsule Increase Frequency of Seed Loss?, B. Bashir, A.
Chowdhury, D. Drachenberg, accepted for publication September, 2008

Prostate-Specific Antigen Bounce After Permanent Radioiodine (I-125) Seed Implants for Clinically Localized
Prostate Cancer, J. Yousuf, K. Malkoske, J. Bews, G. Schroeder, P. Cho, D. Drachenberg, A. Chowdhury,
accepted for publication September, 2008

Radioiodine Seed Migration After Permanent Prostate Brachytherapy, B. Bashir, A. Chowdhury, D.
Drachenberg, accepted for publication September, 2008

Impact of prostate gland edema on post-permanent implant dosimetry: First two years of manitoba experience.
A. Ong, T. Al-Essawi, J. Bews. K. Malkoske G. Schroeder, P. Cho, D. Drachenberg, A. Chowdhury.
Radiotherapy & Oncology Journal 80(1): September 2006
12

Acute morbidity following permanent radio-iodine seed implant for localized prostate cancer. F. Iqbal, A.
Dubey, G. Schroeder, J. Bews, K. Malkoske, P. Cho, D. Drachenberg, A Chowdhury. Radiotherapy &
Oncology Journal 80(1): September 2006

Pulmonary embolization of radioiodine seeds following permanent prostate brachytherapy. T. Dufan, B.
Bashir, J. Bews, K. Malkoske, G. Schroeder, P. Cho, D. Drachenberg, A. Chowdhury. Radiotherapy &
Oncology Journal 80(1): September 2006

Changes in Prostate Volume Post-Permanent seed implantation and its impact on Radiation Dose Distribution.
T. Al Essawi, A. Chowdury, G. Schroeder, J. Bews, M. Malkoske, D. Drachenberg. The Canadian Journal of
Urology 13(3): 3075, 2006

The Use of Ligasure V Vessel Sealing System for Laparoscopic Urological Surgery,D. Yu, D. Drachenberg
The Canadian Journal of Urology 13(3): 3092, 2006

Timelines for the Management of Stage 1 Testicular Germ Cell Cancer: A Canadian Multidisciplinary Survey.
K. Mattar, D. Drachenberg, P. Czaykowski. The Canadian Journal of Urology 13(3): 3096, 2006

Upfront Nephrectomy for Metastatic Renal Cell Carcinoma: The Winnipeg Experience.
MacMahon, DE Drachenberg. The Canadian Journal of Urology 12(3): 2644, 2005

The Natural History of Incidentally Detected Renal Masses < 4 CM. G Sandhu, K Mattar, R MacMahon, D
Drachenberg. The Canadian Journal of Urology 12(3): 2631, 2005

Heterogeneous expression of MN/CA9-G250 Tumor- associated antigen in Renal Cell Carcinoma. DE
Drachenberg, OJ Mena, SV Ivanov, WM Linehan, RW Childs. Journal of Urology 167(4): 504A, 2002

Trocar-Related Mortality in Laparoscopic Surgery. J Veale, D Drachenberg. The Canadian Journal of Urology
10(3): 1855, 2003

Donor T-cells mediate regression of metastatic renal cell carcinoma (RCC) following Non-myeloablative
allogeneic stem cell transplantation. OJ Mena, C Carvallo, DE Drachenberg, R Srinivasin, T Igarashi, WM
Linehan, RW Childs. Journal of Urology 167(4): 492A, 2002

MN/CA9/G250 expression and Von Hippel-Lindau mutation status in sporadic and hereditary renal cell
carcinoma. DE Drachenberg, AA Velasco, MT Zincke, RW Childs, WM Linehan, Journal of Urology 165(5):
500A; 2001.

Autoimmune prostatitis after transfection with probasin and probasin/IL12 constructs through gene gun
imunization and direct IM injections in rats. DE Drachenberg, DG Bell, G Rowden, K West, Journal of
Urology 165(5): 566A; 2001.

Heterogeneous expression of G250 Tumor-associated antigen in Renal Cell Carcinoma. DE Drachenberg, AA
Velasco, T Igarashi, F Re, OJ Mena, WM Linehan, RW Childs, Proceedings of the American Society of Clinical
Oncology 20(1): 2447; 2001.

Generation of cellular immune responses against renal cell carcinoma tumor associated antigen G250 by
adenoviral transduction of dendritic cells. AA Velasco, DE Drachenberg, Z Guo, T Igarashi, A Chernoff, OJ
Mena, WM Linehan, RW Childs, Journal of Urology 165(5): 509A; 2001.

Parenchymal Sparing Surgery for Central Renal Tumors in Patients with Hereditary Renal Cancers. OJ Mena,
DE Drachenberg, PL Choyke, WM Linehan, MM Walther, Journal of Urology 165(5): 661A; 2001.

Adjustments to Impaired Sexual Function after Radical Prostatectomy
Journal of Urology 161(4): 179A; 1999.

Telomerase Activity in Bladder Cancer and Exfoliated Cells in Voided Urine DE. Drachenberg, C Nguan,
DGBell, D Guernsay; Canadian Journal of Urology June 1999

Prostate Cancer Screening : Has the Proportion of Abnormal PSA Values Changed During the PSA Era? DE.
Drachenberg and MK Brawer; Canadian Journal of Urology June 1999

Patient Satisfaction After Hypospadius Repair DE. Drachenberg, PW. Wentzell, Canadian Journal of Urology
June 1998.
K Mattar, R.
DE. Drachenberg, J. Grantmyre,
13

Adjustments to Impaired Sexual Function after Radical Prostatectomy
Canadian Journal of Urology June 1998.

Adjustments to Impaired Sexual Function after Radical Prostatectomy DE. Drachenberg, J. Grantmyre, Issues
and Controversies in Prostate Cancer, 1997 World Conference

Ability of Serum PSA to Predict Normal Bone Scans in Untreated Prostate Cancer M.E. Gleave, DE.
Drachenberg, D.B. Coupland, L.D. Sullivan, S.L. Goldenberg , Journal of Urology 151: 341A, 1994.

Ability of Serum PSA to Predict Normal Bone Scans in Untreated Prostate Cancer M.E. Gleave, DE.
Drachenberg, D.B. Coupland, L.D. Sullivan, S.L. Goldenberg , Canadian Journal of Urology 1(3) : July, 1994.

Clinical Predictors of Pathologic Stage in Clinically Confined Prostate Cancer, M.E. Gleave, DE.
Drachenberg, S.Goodman, S. L. Goldenberg, L.D. Sullivan, Northwest Urological Society Annual Meeting
1993.
DE. Drachenberg, J. Grantmyre,
14
Abstracts Submitted for 2011

The role of Lymph Node Dissection During Nephrourecterectomy in the Management of Upper Urinary Tract
Urothelial Carcinoma: The Canadian Experience. R J Mason, W. Kassouf, D. Bell, L. Lacombe, A. Kapoor,
N. Jacobsen, A. Fairey, J. Izawa, P. Black, S. Tanguay, J. Chin, A. So, J. Baptiste Lattouf, F. Saad, E.
Matsumoto, D. Drachenberg, I. Cagiannos, Y. Fradet, R. A. Rendon. 2010.

Risk Factors for Bladder Cancer Recurrence after Nephroureterectomies for Upper Tract TCC. L. Lacombe,
W. Kassouf, R. Rendon, N. Jacobsen, A. Fairey, J. Izawa, A. Kapoor, P. Black, S. Tanguay, J. Chin, A. So, J.
Baptiste Lattouf, D. Bell, F. Saad, E. Matsumoto, D. Drachenberg, I. Cagiannos, Y. Fradet. 2010

Comparison of Oncologic Outcomes for Open and Laparoscopic Radical Nephroureterectomy: Results from the
Canadian Upper Tract Collaboration, A.S. Fairey, W. Kassouf, E. Estey, S. Tanguay, R. Rendon, D. Bell, J.
Izawa, J. Chin, A. Kapoor, E. Matsumoto P. Black A. So, J-B. Lattouf, F. Saad, D. Drachenberg, I. Cagiannos,
L. Lacombe, Y. Fradet, N.E.B. Jacobsen.

Adjuvant chemotherapy for upper tract urothelial carcinoma treated with nephroureterectomy: assessment of
adequate renal function and impact on outcom. ,F. A. Yafi, S. Tanguay, R. Rendon, N. Jacobsen, A. Fairey, J.
Izawa, A. Kapoor, P. Black, L. Lacombe, J. Chin, A. So, J. Baptiste Lattouf, D. Bell, Y. Fradet, F. Saad, E.
Matsumoto, D. Drachenberg, I. Cagiannos, W. Kassouf. 2010
Presentations/Visiting Professorships







Chair/Organizer – Canadian Partnership Against Cancer; September 2012. Winnipeg, MB
Canadian Health Care System: A Primer. D. Drachenberg. Northeastern Section of the American Urological
Association, Sept 23, 2010 Pittsburgh Pennsylvania
Chair/ Organizer Western Canada Avodart Advisory board May 2010/ Nov 2010
Visiting Professor- Korea University 2009- Urology Department- Active Surveillance of Prostate Cancer/
Minimally invasive therapies for Prostate Cancer
Session Chair- organizer- Issues and Controversies in Prostate Care 2009 – Forum –Multidisciplinary
Management of Prostate Cancer, Cancun Mexico
Chair/Organizer- Western Annual GenitoUrinary Oncology Forum 2009 Victoria, BC
Canadian Urological Associaition Meeting 2008- Minimally invasive management of Small Renal MassesPodium session Chair and presenter
Courses Completed:
Prostate Cryotherapy course Mayo Clinic Rochester MN- April 2005
Laser Certification Course in Urology Dalhousie University, Halifax, NS - Jan. 1999
Prostate Brachtherapy Course- Northwest Prostate Institute Seattle WA- Dec. 1998
AUA Basic Science Course in Urology-Charlottesville VA- June 1998
Advanced Cardiac Life Support/ Advanced Trauma and Life Support –1995-1996
Examinations:
Royal College of Physicians and Surgeons of Canada Urology Fellowship exam- May 2000
Principles of Surgery Examination-, Royal College of Physicians and Surgeons of Canada, Sept 1997
Licensure of the Medical College of Canada Parts I and II- June 1995/October 1996
Personal Interests:
•Band leader as lead guitar player, keyboardist, vocalist, composer, arranger, and recording engineer
playing live performances at a variety of public venues
•Guitar/Music Instructor - Teaching popular, jazz, classical, and acoustic stylings as well as music
rudiments including theory and harmony.
•Member/Volunteer of Winnipeg Jazz and Blues Society
•Avid snowboarder and skier
•Weight training and jogging three to four times per week.